Technical Analysis for SCYX - SCYNEXIS, Inc.

Grade Last Price % Change Price Change
grade F 6.97 -1.13% -0.08
SCYX closed down 1.13 percent on Friday, August 7, 2020, on 44 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical SCYX trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
Down 3 Days in a Row Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.13%
Outside Day Range Expansion -1.13%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -1.69%
Narrow Range Bar Range Contraction -1.69%
NR7 Range Contraction -1.69%
Inside Day Range Contraction -1.69%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.24%
20 DMA Support Bullish -2.24%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


SCYNEXIS, Inc., a pharmaceutical company, is engaged in the discovery, development, and commercialization of anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug, which has completed Phase I clinical trials for the treatment of serious and life-threatening invasive fungal infections in humans against a range of Candida and Aspergillus fungal species, including drug resistant strains. The company, through its proprietary platform for cyclophilin inhibitors, is also developing clinical stage compounds, including SCY-635, an orally available cyclophilin inhibitor that has demonstrated clinical activity against Hepatitis C virus as a single agent and when dosed in combination with pegylated interferon and ribavirin; and SCY-641, a cyclophilin inhibitor with activity similar to cyclosporine, the active ingredient in Restasis and Optimmune drugs currently approved for dry eye disease in humans and dogs, respectively. In addition, it provides contract research and development services. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was founded in 1999 and is headquartered in Durham, North Carolina.
Medicine Medical Specialties Pharmaceutical Drugs Medication Anti Infectives Hepatitis C Pegylation Dry Eye Disease Interferon

Is SCYX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 14.4
52 Week Low 5.0
Average Volume 96,576
200-Day Moving Average 8.83
50-Day Moving Average 7.48
20-Day Moving Average 6.81
10-Day Moving Average 6.75
Average True Range 0.41
ADX 21.59
+DI 24.01
-DI 26.17
Chandelier Exit (Long, 3 ATRs ) 6.38
Chandelier Exit (Short, 3 ATRs ) 6.81
Upper Bollinger Band 7.49
Lower Bollinger Band 6.13
Percent B (%b) 0.62
BandWidth 19.93
MACD Line -0.13
MACD Signal Line -0.21
MACD Histogram 0.0826
Fundamentals Value
Market Cap 186.25 Million
Num Shares 26.7 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -7.26
Price-to-Sales 193.40
Price-to-Book 1.56
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 7.40
Resistance 3 (R3) 7.37 7.19 7.33
Resistance 2 (R2) 7.19 7.08 7.21 7.31
Resistance 1 (R1) 7.08 7.01 6.99 7.11 7.28
Pivot Point 6.90 6.90 6.86 6.92 6.90
Support 1 (S1) 6.79 6.79 6.70 6.83 6.66
Support 2 (S2) 6.61 6.72 6.63 6.63
Support 3 (S3) 6.50 6.61 6.61
Support 4 (S4) 6.54